"In this era of great opportunity Kendle continues to grow above the market rate, demonstrating our customers' increasing recognition of us as a proven global drug development partner able to connect experienced resources worldwide across multiple therapeutic areas and geographies to solve their clinical development challenges. Our growing global footprint and strength in emerging regions such as Central and Eastern Europe and Latin America, deeply valued by our customers, is demonstrated by the fact that Kendle is now one of only two global CROs to have at least 50 percent of its revenue outside the United States." Dr. Kendle concluded, "As we look to the future we believe that advances in science will result in even greater opportunities for globally connected and experienced CROs with expertise in multiple therapeutic areas, regions and eClinical technologies. We look forward to capitalizing on these exciting opportunities and to the increasing role Kendle will play in making life-saving drugs a reality for patients around the globe."
10 Years of Growth
-- Kendle today is among the world's leading CROs and is the fourth-
largest provider of Phase II-IV clinical development services
-- Kendle has grown from 500 associates in eight locations in August 1997
to more than 3,000 associates today in 48 offices across 26 countries
|SOURCE Kendle International Inc.|
Copyright©2007 PR Newswire.
All rights reserved